Sorrento therapeutics

Sorrento Therapeutics is a development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs.

Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases. Sorrento’s lead programs consist of four Phase III BioSimilar/BioBetter antibodies, which address an established market of more than $13 billion, and two Phase I CAR-T programs for treatment of solid tumors. Sorrento also is advancing a portfolio of adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates (ADCs).

Type
Public
HQ
San Diego, US
Size (employees)
97 (est)
Sorrento therapeutics is headquartered in San Diego, US

Key People at Sorrento therapeutics

Henry Ji

Henry Ji

Director, President and CEO

Sorrento therapeutics Office Locations

Sorrento therapeutics has an office in San Diego
San Diego, US (HQ)
9380 Judicial Dr

Sorrento therapeutics Data and Metrics

Sorrento therapeutics Financial Metrics

Sorrento therapeutics's revenue was reported to be $4.9 m in Q1, 2017
USD

Revenue (Q1, 2017)

4.9 m

Net income (Q1, 2017)

(23.8 m)

EBIT (Q1, 2017)

(23.3 m)

Market capitalization (21-Sep-2017)

126.5 m

Cash (31-Mar-2017)

33.9 m
Sorrento therapeutics's current market capitalization is $126.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

460.1 k3.8 m4.6 m8.2 m

Revenue growth, %

731%20%78%

R&D expense

9 m24 m31.3 m42.2 m

General and administrative expense

6.3 m10 m20.1 m24.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

775 k1.3 m977 k1.2 m1.1 m988 k902 k2.2 m4.9 m

R&D expense

5.3 m5.4 m7.8 m8 m7.2 m7.8 m10.6 m10.2 m14.9 m

General and administrative expense

2.4 m1.9 m2.2 m3.1 m4.7 m4.5 m4.2 m5.3 m11.9 m

Operating expense total

7.7 m7.3 m10.1 m11 m12 m12.3 m14.9 m15.5 m26.8 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

31.7 m71.9 m39 m82.4 m

Current Assets

32.6 m73.9 m141 m89.7 m

PP&E

2.4 m2.3 m7.2 m12.7 m

Goodwill

24 m24 m20.6 m41.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

50.2 m44.3 m60.5 m51.7 m59.1 m20.8 m98.2 m66.5 m33.9 m

Current Assets

51.4 m45.8 m62.2 m53.8 m124.8 m71.7 m146.3 m71.8 m42.1 m

PP&E

2.3 m2.4 m2.5 m2.8 m3.8 m7.4 m9.2 m10.1 m17 m

Goodwill

24 m24 m24 m12.5 m20.6 m20.6 m20.6 m20.6 m36.9 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(21.9 m)(34.7 m)(50.1 m)(63.9 m)

Depreciation and Amortization

1.3 m3.2 m2.4 m2.9 m

Accounts Receivable

(2.2 m)

Inventories

(3.2 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(18.5 m)(26.2 m)(10.4 m)(21.4 m)(23.5 m)(20 m)(66.1 m)14.2 m(23.8 m)

Depreciation and Amortization

1.6 m2.4 m823 k1.4 m1.8 m545 k1.1 m

Accounts Payable

(955 k)(703 k)95 k321 k(352 k)1.8 m3.1 m1.4 m11.6 m

Cash From Operating Activities

(15.5 m)(21.1 m)(8.8 m)(7.6 m)(25.9 m)(20.2 m)(32.4 m)
USDY, 2017

Revenue/Employee

50.2 k

Financial Leverage

5.6 x
Show all financial metrics

Sorrento therapeutics Market Value History

Traffic Overview of Sorrento therapeutics

Sorrento therapeutics Company Life and Culture

You may also be interested in